|
1
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T,
Sohara Y, Sugiyama Y and Mano H: Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature.
448:561–566. 2007.PubMed/NCBI
|
|
2
|
Shinmura K, Kageyama S, Tao H, Bunai T,
Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa
H and Sugimura H: EML4-ALK fusion transcripts, but no NPM-, TPM3-,
CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung
carcinomas. Lung Cancer. 61:163–169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmid K, Oehl N, Wrba F, Pirker R, Pirker
C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung
adenocarcinomas and corresponding locoregional lymph node
metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar
|
|
4
|
Kohno T, Ichikawa H, Totoki Y, Yasuda K,
Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y,
Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H,
Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine
I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J and Shibata T:
KIF5B-RET fusions in lung adenocarcinoma. Nat Med.
18:375–377. 2012. View
Article : Google Scholar
|
|
5
|
Takeuchi K, Soda M, Togashi Y, Suzuki R,
Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim
Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H and Ishikawa Y: RET,
ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lipson D, Capelletti M, Yelensky R, Otto
G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T,
Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F,
Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H,
Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D,
Sheehan CE, Ross JS, Cronin MT, Jänne PA and Stephens PJ:
Identification of new ALK and RET gene fusions from
colorectal and lung cancer biopsies. Nat Med. 18:382–384. 2012.
|
|
7
|
Matsuura S, Shinmura K, Kamo T, Igarashi
H, Maruyama K, Tajima M, Ogawa H, Tanahashi M, Niwa H, Funai K,
Kohno T, Suda T and Sugimura H: CD74-ROS1 fusion transcripts in
resected non-small cell lung carcinoma. Oncol Rep. 30:1675–1680.
2013.PubMed/NCBI
|
|
8
|
Oxnard GR, Binder A and Jänne PA: New
targetable oncogenes in non-small-cell lung cancer. J Clin Oncol.
31:1097–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Casaluce F, Sgambato A, Maione P, Rossi A,
Ferrara C, Napolitano A, Palazzolo G, Ciardiello F and Gridelli C:
ALK inhibitors: a new targeted therapy in the treatment of advanced
NSCLC. Target Oncol. 8:55–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cappellen D, De Oliveira C, Ricol D, de
Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and
Radvanyi F: Frequent activating mutations of FGFR3 in human bladder
and cervix carcinomas. Nat Genet. 23:18–20. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greulich H and Pollock PM: Targeting
mutant fibroblast growth factor receptors in cancer. Trends Mol
Med. 17:283–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh D, Chan JM, Zoppoli P, Niola F,
Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S,
Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K,
Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A,
Rabadan R and Iavarone A: Transforming fusions of FGFR and
TACC genes in human glioblastoma. Science. 337:1231–1235.
2012.PubMed/NCBI
|
|
14
|
Williams SV, Hurst CD and Knowles MA:
Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet.
22:795–803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu YM, Su F, Kalyana-Sundaram S, Khazanov
N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ,
Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury
S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes
DR, Robinson DR and Chinnaiyan AM: Identification of targetable
FGFR gene fusions in diverse cancers. Cancer Discov. 3:636–647.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Majewski IJ, Mittempergher L, Davidson NM,
Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK,
Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ,
Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR,
Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den
Heuvel M and Bernards R: Identification of recurrent FGFR3
fusion genes in lung cancer through kinome-centred RNA sequencing.
J Pathol. 230:270–276. 2013.
|
|
17
|
Liao RG, Jung J, Tchaicha J, Wilkerson MD,
Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN,
Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M and Hammerman PS:
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell
carcinoma. Cancer Res. 73:5195–5205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shinmura K, Goto M, Suzuki M, Tao H,
Yamada H, Igarashi H, Matsuura S, Maeda M, Konno H, Matsuda T and
Sugimura H: Reduced expression of MUTYH with suppressive activity
against mutations caused by 8-hydroxyguanine is a novel predictor
of a poor prognosis in human gastric cancer. J Pathol. 225:414–423.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ulivi P, Romagnoli M, Chiadini E, Casoni
GL, Capelli L, Gurioli C, Zoli W, Saragoni L, Dubini A, Tesei A,
Amadori D and Poletti V: Assessment of EGFR and K-ras
mutations in fixed and fresh specimens from transesophageal
ultrasound-guided fine needle aspiration in non-small cell lung
cancer patients. Int J Oncol. 41:147–152. 2012.
|
|
21
|
Mantripragada K and Khurshid H: Targeting
genomic alterations in squamous cell lung cancer. Front Oncol.
3:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pros E, Lantuejoul S, Sanchez-Verde L,
Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC,
Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S,
Brambilla E and Sanchez-Cespedes M: Determining the profiles and
parameters for gene amplification testing of growth factor
receptors in lung cancer. Int J Cancer. 133:898–907. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Intini D, Baldini L, Fabris S, Lombardi L,
Ciceri G, Maiolo AT and Neri A: Analysis of FGFR3 gene
mutations in multiple myeloma patients with t(4;14). Br J Haematol.
114:362–364. 2001.
|
|
24
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007.PubMed/NCBI
|
|
25
|
Yeudall WA, Vaughan CA, Miyazaki H,
Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA,
Deb SP, Windle B and Deb S: Gain-of-function mutant p53 upregulates
CXC chemokines and enhances cell migration. Carcinogenesis.
33:442–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bromberg Y and Rost B: SNAP: predict
effect of non-synonymous polymorphisms on function. Nucleic Acids
Res. 35:3823–3835. 2007. View Article : Google Scholar : PubMed/NCBI
|
